Clorox Co vs Hims and Hers Health Inc — how do they compare? Clorox Co trades at $105.82 (market cap $13.09B), while Hims and Hers Health Inc trades at $29.65 (market cap $7.12B). The key difference: Clorox Co is the larger of the two by market cap, and Clorox Co pays a 4.62% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| CLX | HIMS | |
|---|---|---|
Market Cap | $13.09B | $7.12B |
Sector | Consumer Staples | Health |
52-Week High | $127.16 | $62.76 |
52-Week Low | $86.12 | $14.52 |
Enterprise Value | $18.47B | $7.82B |
Dividend Yield | 4.62% | — |
Signals from Pluang's Aura AI — not financial advice
Clorox (CLX) trades at $107.70, up 2.43% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations, though Q4 2025 missed. The company maintains solid profitability with a net margin of 8.74% and ROE of 285.64%, but faces high P/B of 145.45. News highlights Q4 sales beat and a dividend increase to $1.25 per share, while inflation and consumer value-seeking pose challenges.
Outlook is mixed: improving market share and strategic initiatives support growth, but inflation and competitive pressures risk margins. Analyst consensus is cautious with a hold-heavy rating and $97.50 price target below current levels. Key risks include supply-chain inflation and weak organic sales, requiring careful monitoring of execution against guidance.
HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.
The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.
Trailing returns across standard periods
Latest headlines on both assets
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →